MOTS-cLongevity

MOTS-c (Mitochondrial ORF of the 12S rRNA type-c) is a 16-amino-acid mitochondrial-derived peptide, first characterized by Lee and colleagues in 2015. It regulates metabolic homeostasis, insulin sensitivity and skeletal-muscle energy metabolism, and is often described as an "exercise mimetic" because endogenous levels rise with physical activity. It is sold strictly as a research chemical: not an approved drug and not evaluated by the FDA, with an evidence base that is overwhelmingly preclinical.

MOTS-c promotes glucose utilization largely by activating the AMPK pathway, in part by interfering with the folate-AICAR one-carbon metabolic cycle, increasing skeletal-muscle glucose uptake and GLUT4 expression. Under metabolic stress (glucose restriction, oxidative stress) it translocates to the nucleus in an AMPK-dependent manner and regulates antioxidant-response genes via stress-responsive transcription factors including NRF2. These mechanisms come from cell and rodent models, not human dosing studies.

The evidence base is overwhelmingly preclinical. In mice, MOTS-c administration prevented high-fat-diet- and age-induced insulin resistance, reduced diet-induced obesity, and improved treadmill performance across ages. Human data are limited and observational: exercise raises endogenous muscle and serum MOTS-c, but there are no interventional or dosing trials of exogenous MOTS-c, and a 2023 review confirms no validated clinical application has been developed.

Human safety is essentially unstudied — there are no published interventional human trials, toxicology data or established dosing for exogenous MOTS-c, so its human risk profile is unknown. Pharmacokinetics are poorly characterized and no formal human half-life is established; as a small peptide it is expected to be cleared rapidly. Numeric half-life or dosing figures on vendor sites are not supported by peer-reviewed pharmacokinetic studies. Research use only; nothing here is therapeutic or dosing guidance.